Accessibility Menu
OnKure Therapeutics logo

OnKure Therapeutics(NASDAQ) OKUR

Current Price$4.20
Market Cap$168.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-78%
5 YearN/A
1 Year+80%
1 Month-7%
OnKure Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.172026-07-21
OnKure Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.18%USD 4.222026-07-14
1 month-6.92%USD 4.482026-06-18
3 month-16.77%USD 5.012026-04-22
Year to date+43.79%USD 2.902025-12-31
1 year+79.74%USD 2.322025-07-21
Since inception-77.91%USD 18.652024-10-07

OnKure Therapeutics Financials at a Glance

Market Cap

$168.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$58.75M

EPS (TTM)

-$4.33

P/E Ratio

-0.96

Dividend

$0.00

Beta (Volatility)

0.91 (Low)

Price

$4.20

Volume

4,105

Open

$4.00

Previous Close

$4.20

Daily Range

$4.00 - $4.21

52-Week Range

$1.91 - $5.38

Estimated Earnings Date

Aug 11, 2026

OKUR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OnKure Therapeutics

OnKure develops medicines for people with cancer who have few treatment options. OnKure’s main drug candidates target specific genetic changes in tumors, aiming to treat cancers underserved by available therapies.

Lab Bench to Bedside: What OnKure Makes

OKI-219 (Lead candidate): Drug in early testing for cancers with a specific PI3Kα gene mutation; no revenue yet.

PI3Kα Mutation Programs: Early-stage research on drugs for other PI3Kα gene changes; no commercial sales.

Discontinued Programs: OKI-179 and mavodelpar, both stopped in 2024; no longer in development.

Growth Spurts and Strategic Moves

Completed merger with Reneo Pharmaceuticals in October 2024, combining resources and pipelines.

Raised $65 million in October 2024 through a private share sale after the merger.

Started first human trial for OKI-219 in 2024, focusing on advanced solid tumors.

Ended all work on mavodelpar and terminated the related license in October 2024.

What Makes OnKure Stand Out in the Crowd

OnKure uses computer-based drug design to develop therapies that target specific genetic mutations. The company relies on partnerships and outside labs for research and manufacturing.

Five Things You Need to Know

No product sales or revenue as of September 30, 2024.

Net loss of $17.5 million (GAAP) for the nine months ended September 2024.

Operating expenses were $20.6 million for the nine months ended September 30, 2024, down from $58 million for the same period in 2023.

Cash and investments totaled $76.7 million at September 30, 2024 (Q3 2024, GAAP).

Bottom Line

OnKure is an early-stage biotech focused on precision cancer drugs. The company’s future depends on advancing its lead candidate and managing costs.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

45

CEO

Nicholas A. Saccomano, PhD

Website

onkuretherapeutics.com

Headquarters

Boulder, CO 80301, US

OKUR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-61.02%

Return on Capital

-110.96%

Return on Assets

-29.57%

Earnings Yield

-1.04%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$168.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.40M

Volume

4.11K

Avg. Volume

300.87K

Financials (TTM)

Gross Profit

-$203.00K

Operating Income

-$61.57M

EBITDA

-$57.92M

Operating Cash Flow

-$50.76M

Capital Expenditure

-$33.00K

Free Cash Flow

-$50.79M

Cash & ST Invst.

$192.11M

Total Debt

$409.00K

OnKure Therapeutics Performance Analysis

OnKure Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
OnKure Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
OnKure Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -21.21-3.2%
20232023-12-31USD -1,125.465206.5%
20242024-12-31USD -3.95-99.6%
20252025-12-31USD -4.4011.6%
OnKure Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-304.2%
Q32025-09-304.4%
Q42025-12-319.2%
Q12026-03-31-12.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$203.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$168.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.74M

N/A

Employees

45

N/A

Net Income

-$15.16M

+4.8%

EBITDA

-$14.95M

+4.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$192.11M

+98.7%

Total Debt

$409.00K

-57.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$409.00K

-25.1%

Return on Assets

-29.57%

N/A

Return on Invested Capital

-33.39%

N/A

Free Cash Flow

-$12.94M

+7.7%

Operating Cash Flow

-$12.94M

+7.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MRSNMersana Therapeutics, Inc.
$29.08+0.00%
XLOXilio Therapeutics, Inc.
$8.70+1.52%
KZRKezar Life Sciences, Inc.
$7.29+0.00%
PDSBPDS Biotechnology Corporation
$0.76+5.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$7.66+0.11%
PATHUiPath
$12.04-0.01%
TAT&T
$22.26+0.01%
MARAMara Holdings
$12.25+0.05%

Questions About OKUR

What is the current price of OnKure Therapeutics?

OnKure Therapeutics is trading at $4.20 per share.

What is the 52-week range for OnKure Therapeutics?

Over the past 52 weeks, OnKure Therapeutics has traded between $1.91 and $5.38.

How much debt does OnKure Therapeutics have?

As of the most recent reporting period, OnKure Therapeutics reported total debt of $409.00K.

How much cash does OnKure Therapeutics have on hand?

OnKure Therapeutics reported $192.11M in cash and cash equivalents in its most recent financial results.

What is OnKure Therapeutics’s dividend yield?

OnKure Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services